隐球菌感染诊治专家共识

摘要/Abstract

摘要： 隐球菌属在真菌分类学上归入半知菌亚门、芽孢菌纲、隐球酵母目、隐球酵母科,引起人类感染的隐球菌主要是新生隐球菌和格特隐球菌。两种隐球菌的无性繁殖体均为无菌丝的单芽孢酵母样菌,在体外为无荚膜或仅有小荚膜,进入人体内后很快形成厚荚膜,有荚膜的隐球菌菌体直径明显增加,致病力明显增强。隐球菌可以感染人体的任何组织和脏器,最常见的部位是中枢神经系统,其次为肺部和皮肤。目前,在免疫抑制患者中,隐球菌感染的发病率约为5%～10%,在AIDS患者中,隐球菌的感染率可以高达30%;而在免疫功能正常的人群中,隐球菌的感染率约为十万分之一左右^[1]。在加拿大曾经发生格特隐球菌感染在正常人群和动物中大流行^[2]。

中图分类号:

R756.6

《中国真菌学杂志》编辑委员会. 隐球菌感染诊治专家共识[J]. 中国真菌学杂志, 2010, 5(2): 65-68,86.

参考文献

[1] Mitchell TG,Perfect JR.Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans[J].Clin Microbiol Rev,1995,8:515-548.
[2] James A,Fraser Steven S,Giles Emily C,et al.Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak[J].Nature,2005,437:1360-1364[3] Huston SM,Mody CH.Cryptococcosis:an emerging respiratory mycosis[J].Clin Chest Med,2009,30(2):253-264.
[4] Shirley RM,Baddley JW.Cryptococcal lung disease[J].Curr Opin Pulm Med,2009,15(3):254-260.
[5] Yamada H,Kotaki H,Takahashi T.Recommendations for the treatment of fungal pneumonias[J].Expert Opin Pharmacother,2003,4(8):1241-1258.
[6] Chang WC,Tzao C,Hsu HH,et al.Pulmonary cryptococcosis:comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients[J].Chest,2006,129(2):333-340.
[7] Perfect JR,Dismukes WE,Dromer F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of America[J].Clin Infect Dis,2010,50(3):291-322.
[8] Neuville S,Dromer F,Morin O,et al.Primary cutaneous cryptococcosis:a distinct clinical entity[J].Clin Infect Dis,2003,36(3):337-347.
[9] John C Christianson,William Engber,David Andes.Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts[J].Med Mycol,2003,41:180-188.
[10] Revenga F,Paricio JF,Merino FJ.Primary cutaneous cryptococcosis in an immunocompetent host:case report and review of the literature[J].Dermatology,2002,204 (2):145-149.
[11] Saag MS,Grayb-Ⅱ RJ,Larsen RA,et al.Practice guidline for the management of cryptococcal disease[J].Clin Infect Dis,2000,30(4):710-718.
[12] Dromer F,Bernede-Bauduin C,Guillemot D,et al.For the French Cryptococcosis Study Group(2008) Major Role for Amphotericin B Fhcytosine Combination in Severe Cryptococcosis[J].PLoS ONE,3(8):e2870.
[13] Singh N,Lortholary O,Alexander BD,et al.Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection[J].Transplantation,2005,80:1033-1039.
[14] Pappas PG.Managing cryptococcal meningitis is about handling the pressure[J].Clin Infect Dis,2005,40:480-482.
[15] 朱元杰,张俊勇,顾菊林,等.非艾滋病患者隐球菌脑膜炎治疗与随访过程中真菌学指标分析[J].中华传染病杂志,2009,27(9):29-31.
[16] 沈银忠,齐唐凯,张仁芳,等.艾滋病合并隐球菌脑膜炎的临床特点及预后[J].中华传染病杂志,2009,27(1):45-47.
[17] 沈银忠,卢洪洲,齐唐凯,等.两性霉素B联合氟胞嘧啶与伏立康唑治疗艾滋病合并隐球菌脑膜炎的临床回顾性研究[J].中国真菌学杂志,2009,4(6):338-342.
[18] Vibhagool A,Sungkanuparph S,Mootsikapun P,et al.Discon-tinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy:a prospective,multicenter,randomized study[J].Clin Infect Dis,2003,36 (10):1329-1331.
[19] 卢洪洲,郑毓芳,沈银忠.艾滋病合并隐球菌性脑膜炎的治疗原则初探[J].中国真菌学杂志,2008,3(4):193-196.